Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$166.51 USD

166.51
586,950

-3.32 (-1.95%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $166.38 -0.13 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Key Expected Earnings Data

Report Date Period Ending Zacks Consensus Estimate Earnings ESP
11/06/2025

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.


Time: -- 		9/2025 $1.96 1.36%

Earnings Summary

For their last quarter, Ligand Pharmaceuticals (LGND) reported earnings of $1.60 per share, beating the Zacks Consensus Estimate of $1.54 per share. This reflects a positive earnings surprise of 3.90%. Look out for LGND's next earnings release expected on November 06, 2025. For the next earning release, we expect the company to report earnings of $1.96 per share, reflecting a year-over-year increase of 602.56%.

Earnings History

*BMO: Before Market Open

*AMC: After Market Close

Price & Consensus

LGND FAQs

Based on past history, Zacks believes Ligand Pharmaceuticals Incorporated (LGND) will report their next quarter earnings on November 06, 2025. For the next earning release, we expect the company to report earnings of 1.96 per share, reflecting a year-over-year increase of 602.56.

Based on past history, Zacks believes Ligand Pharmaceuticals Incorporated (LGND) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 06, 2025.

The Zacks Consensus Estimate for Ligand Pharmaceuticals Incorporated (LGND) for the quarter ending in September 2025 is $1.96 a share. We expect Ligand Pharmaceuticals Incorporated to miss by 1.36%.

In the earnings report for the quarter ending in June 2024, Ligand Pharmaceuticals Incorporated (LGND) announced earnings of $1.40 per share versus the Zacks Consensus Estimate of $1.10 per share, representing a surprise of 27.27%.